3:29 PM
 | 
Jul 20, 2018
 |  BC Extra  |  Company News

PureTech, Roche to use exosomes for oral drug delivery

PureTech Health plc (LSE:PRTC) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to develop PureTech's milk-derived exosome platform to orally deliver Roche's antisense oligonucleotides.

PureTech will receive up to $36 million comprising an upfront payment, early preclinical milestone payments and research support. The company is also eligible to receive over $1...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >